Stifel Nicolaus Begins Coverage on COMPASS Pathways (NASDAQ:CMPS)

Research analysts at Stifel Nicolaus started coverage on shares of COMPASS Pathways (NASDAQ:CMPS) in a research note issued on Thursday, MarketBeat Ratings reports. The brokerage set a “buy” rating and a $11.00 price target on the stock. Stifel Nicolaus’ price target points to a potential upside of 179.90% from the company’s previous close.

Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada reiterated an “outperform” rating and issued a $18.00 price target on shares of COMPASS Pathways in a report on Wednesday, January 15th. Maxim Group cut their price target on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st. Finally, HC Wainwright dropped their target price on shares of COMPASS Pathways from $60.00 to $45.00 and set a “buy” rating for the company in a report on Thursday, February 13th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $21.83.

COMPASS Pathways Stock Up 0.3 %

CMPS stock opened at $3.93 on Thursday. COMPASS Pathways has a one year low of $3.16 and a one year high of $12.57. The stock has a market capitalization of $268.89 million, a PE ratio of -1.79 and a beta of 2.28. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The company has a fifty day moving average of $4.06 and a 200-day moving average of $5.26.

COMPASS Pathways (NASDAQ:CMPS) last released its earnings results on Thursday, February 27th. The company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). As a group, analysts expect that COMPASS Pathways will post -2.33 EPS for the current year.

Hedge Funds Weigh In On COMPASS Pathways

Several hedge funds have recently added to or reduced their stakes in CMPS. RTW Investments LP purchased a new position in COMPASS Pathways during the 4th quarter valued at about $11,714,000. Altium Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth about $5,384,000. Tang Capital Management LLC acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth about $3,780,000. Nantahala Capital Management LLC boosted its stake in shares of COMPASS Pathways by 400.0% during the 4th quarter. Nantahala Capital Management LLC now owns 1,000,000 shares of the company’s stock worth $3,780,000 after purchasing an additional 800,000 shares during the last quarter. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of COMPASS Pathways during the 4th quarter worth about $2,458,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.